FavoriteLoadingAdd to favorites

Sanofi And GSK Launch Final Testing Phase Of New Covid Vaccine

And GSK Launch Final Testing Phase Of New Covid Vaccine

Sanofi And GSK Launch Final Testing Phase Of New Covid Vaccine

The trial will include 35,000 people from Asia, Africa, USA and Latin America (File Photo)

:

French pharmaceutical giant Sanofi and Britain’s GSK announced Thursday the start of final tests of their belated Covid vaccine as they race to add their jab to the world’s arsenal against the pandemic.

The companies reported positive results from interim human trials earlier this month after a disappointing outcome from initial studies last year left without its own vaccine, denting national pride.

Sanofi and GlaxoSmithKline on Thursday started enrolment for Phase 3 of a clinical study that will include more than 35,000 adult volunteers at sites in the , Asia, Africa and Latin America, the firms said.

The companies hope to launch their vaccine by the end of 2021 — one year after Pfizer and Moderna jabs were approved by regulators.

The Phase 3 trial will initially investigate the vaccine’s efficacy against the original coronavirus that was first detected in Wuhan, China and then look at its response to a variant found in South Africa.

Sanofi and GSK will also study their vaccine’s ability to as a in people had previously received another vaccine.

The Phase 2 trials already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus.

“We have adapted our vaccine development strategy based on forward-looking considerations as the virus continues to evolve, as well as anticipating what may be needed in a post-pandemic setting,” Sanofi executive vice Thomas Triomphe said in a statement.

Like most of the other jabs in circulation, the Sanofi-GSK vaccine would require two doses.

Promoted

Listen to the latest songs, only on JioSaavn.com

The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

(Except for the headline, this has not been edited by NDTV staff and is published from a syndicated feed.)

 

Related posts

administrator

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *